1
|
Boichenko MA, Plodukhin AY, Shorokhov VV, Lebedev DS, Filippova AV, Zhokhov SS, Tarasenko EA, Rybakov VB, Trushkov IV, Ivanova OA. Synthesis of 1,5-Substituted Pyrrolidin-2-ones from Donor-Acceptor Cyclopropanes and Anilines/Benzylamines. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27238468. [PMID: 36500574 PMCID: PMC9735934 DOI: 10.3390/molecules27238468] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/29/2022] [Revised: 11/16/2022] [Accepted: 11/23/2022] [Indexed: 12/12/2022]
Abstract
We developed a straightforward synthetic route to pharmacologically important 1,5-substituted pyrrolidin-2-ones from donor-acceptor cyclopropanes bearing an ester group as one of the acceptor substituents. This method includes a Lewis acid-catalyzed opening of the donor-acceptor cyclopropane with primary amines (anilines, benzylamines, etc.) to γ-amino esters, followed by in situ lactamization and dealkoxycarbonylation. The reaction has a broad scope of applicability; a variety of substituted anilines, benzylamines, and other primary amines as well as a wide range of donor-acceptor cyclopropanes bearing (hetero)aromatic or alkenyl donor groups and various acceptor substituents can be involved in this transformation. In this process, donor-acceptor cyclopropanes react as 1,4-C,C-dielectrophiles, and amines react as 1,1-dinucleophiles. The resulting di- and trisubstituted pyrrolidin-2-ones can be also used in subsequent chemistry to obtain various nitrogen-containing polycyclic compounds of interest to medicinal chemistry and pharmacology, such as benz[g]indolizidine derivatives.
Collapse
Affiliation(s)
- Maksim A. Boichenko
- Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia
| | - Andrey Yu. Plodukhin
- Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia
| | - Vitaly V. Shorokhov
- Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia
| | - Danyla S. Lebedev
- Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia
| | - Anastasya V. Filippova
- Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia
| | - Sergey S. Zhokhov
- Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia
| | - Elena A. Tarasenko
- Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia
| | - Victor B. Rybakov
- Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia
| | - Igor V. Trushkov
- N. D. Zelinsky Institute of Organic Chemistry, Leninsky Pr. 47, 119334 Moscow, Russia
- Correspondence: (I.V.T.); (O.A.I.); Tel.: +7-916-645-9951 (I.V.T.)
| | - Olga A. Ivanova
- Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russia
- Correspondence: (I.V.T.); (O.A.I.); Tel.: +7-916-645-9951 (I.V.T.)
| |
Collapse
|
2
|
Andreev I, Boichenko M, Ratmanova N, Ivanova O, Levina I, Khrustalev V, Sedov I, Trushkov I. 4‐(Dimethylamino)pyridinium Azide in Protic Ionic Liquid Media as a Stable Equivalent of Hydrazoic Acid. Adv Synth Catal 2022. [DOI: 10.1002/adsc.202200486] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Ivan Andreev
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology Oncology and Immunology RUSSIAN FEDERATION
| | - Maksim Boichenko
- Lomonosov Moscow State University Department of Chemistry RUSSIAN FEDERATION
| | - Nina Ratmanova
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology Oncology and Immunology RUSSIAN FEDERATION
| | | | - Irina Levina
- FSBSI Institute of Biochemical Physics named after N M Emanuel of the Russian Academy of Sciences RUSSIAN FEDERATION
| | | | - Igor Sedov
- Kazan Federal University RUSSIAN FEDERATION
| | - Igor Trushkov
- N.D. Zelinsky Institute of Organic Chemistry RUSSIAN FEDERATION
| |
Collapse
|
3
|
Yaeger JD, Krupp KT, Gale JJ, Summers CH. Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity. MEDICINE IN DRUG DISCOVERY 2020. [DOI: 10.1016/j.medidd.2020.100059] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
|
4
|
Shikora JM, Chemler SR. Synthesis of Benzyl Amines via Copper-Catalyzed Enantioselective Aza-Friedel-Crafts Addition of Phenols to N-Sulfonyl Aldimines. Org Lett 2018; 20:2133-2137. [PMID: 29589946 DOI: 10.1021/acs.orglett.8b00282] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
A new copper-catalyzed enantioselective aza-Freidel-Crafts reaction between phenols and N-sulfonyl aldimines that provides chiral secondary benzylamines in good to excellent yields and excellent enantioselectivities (up to 99% ee) is disclosed. In particular, excellent scope with alkylimines was observed for the first time. The synthetic utility of the products was demonstrated in the first enantioselective synthesis of a dual orexin receptor antagonist, a compound that contains an amine-bearing stereocenter adjacent to a bis- ortho-functionalized arene.
Collapse
Affiliation(s)
- Jonathan M Shikora
- Chemistry Department, Natural Science Complex , State University of New York at Buffalo , Buffalo , New York 14260 , United States
| | - Sherry R Chemler
- Chemistry Department, Natural Science Complex , State University of New York at Buffalo , Buffalo , New York 14260 , United States
| |
Collapse
|
5
|
Boichenko MA, Ivanova OA, Andreev IA, Chagarovskiy AO, Levina II, Rybakov VB, Skvortsov DA, Trushkov IV. Convenient approach to polyoxygenated dibenzo[c,e]pyrrolo[1,2-a]azepines from donor–acceptor cyclopropanes. Org Chem Front 2018. [DOI: 10.1039/c8qo00742j] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A convenient approach to polyoxygenated tetrahydrodibenzo[c,e]pyrrolo[1,2-a]azepines from the donor–acceptor cyclopropanes has been developed.
Collapse
Affiliation(s)
- Maksim A. Boichenko
- Department of Chemistry
- M. V. Lomonosov Moscow State University
- Moscow 119991
- Russian Federation
| | - Olga A. Ivanova
- Department of Chemistry
- M. V. Lomonosov Moscow State University
- Moscow 119991
- Russian Federation
| | - Ivan A. Andreev
- Laboratory of Chemical Synthesis
- Dmitry Rogachev National Research Center of Pediatric Hematology
- Oncology and Immunology
- Moscow 117997
- Russian Federation
| | - Alexey O. Chagarovskiy
- Laboratory of Chemical Synthesis
- Dmitry Rogachev National Research Center of Pediatric Hematology
- Oncology and Immunology
- Moscow 117997
- Russian Federation
| | - Irina I. Levina
- N. M. Emanuel Institute of Biochemical Physics
- Russian Academy of Sciences
- Moscow 119334
- Russian Federation
| | - Victor B. Rybakov
- Department of Chemistry
- M. V. Lomonosov Moscow State University
- Moscow 119991
- Russian Federation
| | - Dmitriy A. Skvortsov
- Department of Chemistry
- M. V. Lomonosov Moscow State University
- Moscow 119991
- Russian Federation
| | - Igor V. Trushkov
- Laboratory of Chemical Synthesis
- Dmitry Rogachev National Research Center of Pediatric Hematology
- Oncology and Immunology
- Moscow 117997
- Russian Federation
| |
Collapse
|
6
|
Recent advance in oxazole-based medicinal chemistry. Eur J Med Chem 2018; 144:444-492. [DOI: 10.1016/j.ejmech.2017.12.044] [Citation(s) in RCA: 166] [Impact Index Per Article: 27.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2017] [Revised: 12/04/2017] [Accepted: 12/13/2017] [Indexed: 01/09/2023]
|
7
|
Heidmann B, Gatfield J, Roch C, Treiber A, Tortoioli S, Brotschi C, Williams JT, Bolli MH, Abele S, Sifferlen T, Jenck F, Boss C. Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach. ChemMedChem 2016; 11:2132-2146. [DOI: 10.1002/cmdc.201600175] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2016] [Revised: 05/18/2016] [Indexed: 01/04/2023]
Affiliation(s)
- Bibia Heidmann
- Actelion Pharmaceuticals Ltd.; Drug Discovery and Preclinical Research & Development; Gewerbestrasse 16 4123 Allschwil Switzerland
| | - John Gatfield
- Actelion Pharmaceuticals Ltd.; Drug Discovery and Preclinical Research & Development; Gewerbestrasse 16 4123 Allschwil Switzerland
| | - Catherine Roch
- Actelion Pharmaceuticals Ltd.; Drug Discovery and Preclinical Research & Development; Gewerbestrasse 16 4123 Allschwil Switzerland
| | - Alexander Treiber
- Actelion Pharmaceuticals Ltd.; Drug Discovery and Preclinical Research & Development; Gewerbestrasse 16 4123 Allschwil Switzerland
| | - Simone Tortoioli
- Actelion Pharmaceuticals Ltd.; Drug Discovery and Preclinical Research & Development; Gewerbestrasse 16 4123 Allschwil Switzerland
| | - Christine Brotschi
- Actelion Pharmaceuticals Ltd.; Drug Discovery and Preclinical Research & Development; Gewerbestrasse 16 4123 Allschwil Switzerland
| | - Jodi T. Williams
- Actelion Pharmaceuticals Ltd.; Drug Discovery and Preclinical Research & Development; Gewerbestrasse 16 4123 Allschwil Switzerland
| | - Martin H. Bolli
- Actelion Pharmaceuticals Ltd.; Drug Discovery and Preclinical Research & Development; Gewerbestrasse 16 4123 Allschwil Switzerland
| | - Stefan Abele
- Actelion Pharmaceuticals Ltd.; Drug Discovery and Preclinical Research & Development; Gewerbestrasse 16 4123 Allschwil Switzerland
| | - Thierry Sifferlen
- Actelion Pharmaceuticals Ltd.; Drug Discovery and Preclinical Research & Development; Gewerbestrasse 16 4123 Allschwil Switzerland
| | - François Jenck
- Actelion Pharmaceuticals Ltd.; Drug Discovery and Preclinical Research & Development; Gewerbestrasse 16 4123 Allschwil Switzerland
| | - Christoph Boss
- Actelion Pharmaceuticals Ltd.; Drug Discovery and Preclinical Research & Development; Gewerbestrasse 16 4123 Allschwil Switzerland
| |
Collapse
|
8
|
Montoya-Balbás IJ, Valentín-Guevara B, López-Mendoza E, Linzaga-Elizalde I, Ordoñez M, Román-Bravo P. Efficient Synthesis of β-Aryl-γ-lactams and Their Resolution with (S)-Naproxen: Preparation of (R)- and (S)-Baclofen. Molecules 2015; 20:22028-43. [PMID: 26690390 PMCID: PMC6332160 DOI: 10.3390/molecules201219830] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2015] [Revised: 11/24/2015] [Accepted: 12/02/2015] [Indexed: 01/18/2023] Open
Abstract
An efficient synthesis of enantiomerically-pure β-aryl-γ-lactams is described. The principal feature of this synthesis is the practical resolution of β-aryl-γ-lactams with (S)-Naproxen. The procedure is based on the Michael addition of nitromethane to benzylidenemalonates, which was easily obtained, followed by the reduction of the γ-nitroester in the presence of Raney nickel and the subsequent saponification/decarboxylation reaction. The utility of this methodology was highlighted by the preparation of enantiomerically-pure (R)- and (S)-Baclofen hydrochloride.
Collapse
Affiliation(s)
- Iris J Montoya-Balbás
- Centro de Investigaciones Químicas CIQ-IICBA, Universidad Autónoma del Estado de Morelos, Av. Universidad 1001, 62209 Cuernavaca, Morelos, Mexico.
| | - Berenice Valentín-Guevara
- Centro de Investigaciones Químicas CIQ-IICBA, Universidad Autónoma del Estado de Morelos, Av. Universidad 1001, 62209 Cuernavaca, Morelos, Mexico.
| | - Estefanía López-Mendoza
- Centro de Investigaciones Químicas CIQ-IICBA, Universidad Autónoma del Estado de Morelos, Av. Universidad 1001, 62209 Cuernavaca, Morelos, Mexico.
| | - Irma Linzaga-Elizalde
- Centro de Investigaciones Químicas CIQ-IICBA, Universidad Autónoma del Estado de Morelos, Av. Universidad 1001, 62209 Cuernavaca, Morelos, Mexico.
| | - Mario Ordoñez
- Centro de Investigaciones Químicas CIQ-IICBA, Universidad Autónoma del Estado de Morelos, Av. Universidad 1001, 62209 Cuernavaca, Morelos, Mexico.
| | - Perla Román-Bravo
- Centro de Investigaciones Químicas CIQ-IICBA, Universidad Autónoma del Estado de Morelos, Av. Universidad 1001, 62209 Cuernavaca, Morelos, Mexico.
| |
Collapse
|
9
|
Boss C, Roch C. Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934). Expert Opin Ther Pat 2015; 26:409-15. [PMID: 26593218 DOI: 10.1517/13543776.2016.1124087] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The three patent applications WO2015/055994, WO2015/124932 and WO2015/124934 from Takeda Pharmaceuticals describe antagonists for the orexin-1 receptor, based on saturated substituted five-membered carbo- or heterocycles. According to the patent applications, the compounds have utility in therapeutic areas such as schizophrenia and other psychotic disorders, anxiety or addiction disorders, among others. The patent applications together describe almost 300 examples, and for most of them activity data, determined by Fluorescence Imaging Plate Reader (FLIPR) technology on the orexin-1 as well as the orexin-2 receptor, are disclosed. Structurally, the building blocks used to prepare the compounds are reminiscent of other orexin antagonist programs recently disclosed in the literature. However, the templates used are novel in the orexin antagonist field and are probably the key feature for the selectivity of the derivatives towards the orexin-1 receptor.
Collapse
Affiliation(s)
- Christoph Boss
- a Drug Discovery, Chemistry Technologies and Lead Discovery , Actelion Pharmaceuticals Ltd ., Allschwil , Switzerland
| | - Catherine Roch
- b Drug Discovery, CNS Pharmacology , Actelion Pharmaceuticals Ltd ., Allschwil , Switzerland
| |
Collapse
|
10
|
Abstract
The orexin-1 and orexin-2 receptors are two G protein-coupled receptors that bind the neuropeptides orexin-A and orexin-B. Dual antagonism of the receptors by small molecules is clinically efficacious in the treatment of insomnia, where the most advanced molecule suvorexant has recently been approved. The scope of this article is to review the small molecule orexin receptor antagonist patent literature between January 2012 and January 2014.
Collapse
|
11
|
Abstract
INTRODUCTION The orexin (hypocretin) system is an evolutionarily conserved neuropeptide-G-protein-coupled receptor system, consisting of two neuropeptides the orexin-A and the orexin-B peptides as well as two receptors the orexin-1 and the orexin-2 receptors. The orexin system is crucially involved in the regulation of the circadian rhythm, states of wakefulness and arousal and the modulation of emotions and has attracted the interest of many researchers which resulted in an enormous amount of insight, mainly in the field of antagonists. Clinical proof of concept was obtained with dual orexin receptor antagonists in primary insomnia. Merck's suvorexant got FDA approval on 13 August 2014 for the treatment of insomnia. AREAS COVERED The patent applications from Thomson Reuters Integrity Database (covering 2010-August 2014) are summarized, analyzed and discussed in the review. EXPERT OPINION Intense patenting activities have been observed over the past 3 years in the field of orexin antagonists. Several compounds have been investigated in clinical trials mainly for the treatment of primary insomnia. The advantage of orexin antagonists, based on animal pharmacology results, is the promotion and maintenance of physiological sleep which should avoid hangover phenomena reported as side effects of approved treatments. Many other potential treatment options are mentioned for orexin antagonists of different selectivity profiles.
Collapse
Affiliation(s)
- Christoph Boss
- Drug Discovery and Preclinical Research, Actelion Pharmaceuticals Ltd , Gewerbestrasse 16, CH-4123 Allschwil/ BL , Switzerland
| |
Collapse
|
12
|
Recent trends in orexin research—2010 to 2015. Bioorg Med Chem Lett 2015; 25:2875-87. [DOI: 10.1016/j.bmcl.2015.05.012] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Revised: 05/08/2015] [Accepted: 05/09/2015] [Indexed: 12/31/2022]
|
13
|
Sifferlen T, Boller A, Chardonneau A, Cottreel E, Gatfield J, Treiber A, Roch C, Jenck F, Aissaoui H, Williams JT, Brotschi C, Heidmann B, Siegrist R, Boss C. Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2. Bioorg Med Chem Lett 2015; 25:1884-91. [DOI: 10.1016/j.bmcl.2015.03.035] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2015] [Revised: 03/12/2015] [Accepted: 03/16/2015] [Indexed: 01/08/2023]
|